Cash­ing in on PhII tri­al suc­cess, Are­na to raise $353M to fu­el PhI­II etrasi­mod/ra­linepag tri­als

Tak­ing ad­van­tage of its stock’s hot po­si­tion this week, Are­na $AR­NA is fol­low­ing its promis­ing Phase II da­ta with a pub­lic of­fer­ing that should bring …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.